PF 337210

Drug Profile

PF 337210

Alternative Names: PF-00337210; PF-337210

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Benzofurans; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO, Capsule)
  • 08 Jun 2010 Adverse events, pharmacokinetics, pharmacodynamics and efficacy data from a phase I trial in late-stage Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 11 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top